文献速递妇科肿瘤乳腺癌

Alisertib联合每周紫杉醇治疗晚期乳腺癌或复发性卵巢癌:一项随机临床试验

Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2019-01-10

这项1/2期研究评估了alisertib联合每周紫杉醇在乳腺癌(1期)和卵巢癌(1期和2期)患者中的活性。2期部分随机分配142例复发性卵巢癌患者接受alisertib联合紫杉醇或紫杉醇单药治疗,主要终点为PFS。

要点

  • alisertib联合紫杉醇较单药紫杉醇延长中位PFS(6.7 vs 4.7个月),但差异未达预设统计学阈值。
  • 联合组3级及以上不良事件发生率为86%,显著高于单药组的20%,以中性粒细胞减少和口腔炎为主。
  • 联合组74%患者因不良事件需减量,提示该方案毒性需密切管理。

研究设计与样本

  • 开放标签1期和随机2期临床试验,2010年4月16日至2013年8月12日在美国、法国和波兰的33个中心开展,数据截止2014年8月12日。
  • 共入组191例晚期乳腺癌(仅1期)或复发性卵巢癌女性患者,其中2期随机分配142例至alisertib联合紫杉醇组(n=73)或紫杉醇单药组(n=69)。
  • 随机按1:1分层,分层因素为铂类无治疗间期(难治性、0-6个月、6-12个月)和既往每周紫杉醇治疗(是、否)。
  • alisertib用法为40 mg口服每日两次,用药3天停4天,持续3周;联合紫杉醇60 mg/m2静脉注射,第1、8、15天给药;对照为每周紫杉醇80 mg/m2静脉注射,28天为一周期。
  • 主要终点为PFS,主要疗效和安全性分析采用改良意向治疗人群(mITT,所有接受至少1剂研究药物的随机患者)。

主要发现

  • 2期患者中位年龄:联合组63岁(范围30-81),单药组61岁(范围41-81);1期191例患者中位年龄59岁(范围29-75)。
  • 数据截止时,107例(75%)患者出现PFS事件,联合组52例(71%),单药组55例(80%)。
  • 药物相关3级及以上不良事件:联合组63例(86%)vs 单药组14例(20%),包括中性粒细胞减少56例(77%)vs 7例(10%)、口腔炎18例(25%)vs 0例、贫血10例(14%)vs 2例(3%)。
  • 联合组54例(74%)vs 单药组17例(25%)因不良事件导致剂量降低;研究期间每组各1例患者死亡,均认为与研究药物无关。

关键数值与推荐

  • 3级及以上药物相关不良事件发生率:联合组86% vs 单药组20%;中性粒细胞减少77% vs 10%;口腔炎25% vs 0%;贫血14% vs 3%。
  • 因不良事件减量比例:联合组74% vs 单药组25%。

临床怎么用

  • 对于复发性卵巢癌,alisertib联合每周紫杉醇较单药紫杉醇改善PFS的趋势,但未达到预设统计学显著性阈值,需进一步研究验证。
  • 联合方案毒性显著增加,尤其是中性粒细胞减少和口腔炎,需密切监测血常规和口腔黏膜,并做好剂量调整准备。
  • 该研究为1/2期,样本量有限,结果尚不能直接改变临床实践。

局限性

  • 2期部分样本量较小(142例随机),统计效能有限。
  • 联合组毒性显著更高,剂量降低比例达74%,可能影响治疗依从性和疗效评估。
  • 随访时间较短(联合组中位7.2个月,单药组4.6个月),总生存数据不成熟。
  • 1期仅纳入乳腺癌患者,2期仅纳入卵巢癌患者,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There is an unmet medical need for the treatment of recurrent ovarian cancer, and new approaches are needed to improve progression-free survival (PFS) and overall survival. OBJECTIVE: This phase 1/2 study evaluated the activity of alisertib in combination with weekly paclitaxel in patients with breast (phase 1) and ovarian cancer (phase 1 and phase 2). DESIGN, SETTING, AND PARTICIPANTS: An open-label phase 1 and randomized phase 2 clinical trial conducted from April 16, 2010, for phase 1 and March 28, 2012, to August 12, 2013, for phase 2 was conducted at 33 sites (United States, France, and Poland). Data are reported from a cutoff date of August 12, 2014, with a median duration of follow-up of 7.2 months in the alisertib plus paclitaxel arm and 4.6 months in the paclitaxel arm. A total of 191 women with advanced breast (phase 1 only) or recurrent ovarian cancer were enrolled, including 142 patients randomized to alisertib plus paclitaxel (n = 73) or paclitaxel alone (n = 69) in the phase 2 study. INTERVENTIONS: Patients were randomized 1:1 stratified by platinum-free interval (refractory, 0-6 months, 6-12 months) and prior weekly taxane treatment (yes, no) to receive alisertib 40 mg twice per day orally and 3 days on and 4 days off for 3 weeks, plus paclitaxel (60 mg/m2 intravenously, days 1, 8, and 15), or weekly paclitaxel 80 mg/m2 intravenously in 28-day cycles. MAIN OUTCOMES AND MEASURES: Primary endpoint was PFS; primary efficacy analysis and safety analysis used modified intention to treat (mITT) population (all randomized patients who received ≥1 dose of study drug). RESULTS: The median age for the 191 patients enrolled in phase 1 was 59 (range, 29-75) years. The median age for the 142 patients enrolled in phase 2 was 63 (range, 30-81) years for patients receiving alisertib plus paclitaxel and 61 (range, 41-81) years for patients receiving paclitaxel. At data cutoff, 107 (75%) patients had a documented PFS event; 52 (71%) in the alisertib plus paclitaxel arm, and 55 (80%) in the paclitaxel arm. Median PFS was 6.7 months with alisertib plus paclitaxel vs 4.7 months with paclitaxel (HR, 0.75; 80% CI, 0.58-0.96; P = .14; 2-sided P value cutoff = .20 to be considered worthy of further investigation). Drug-related grade 3 or higher adverse events were reported in 63 (86%) vs 14 (20%) patients in the alisertib plus paclitaxel and paclitaxel arms, including 56 (77%) vs 7 (10%) neutropenia, 18 (25%) vs 0 stomatitis, and 10 (14%) vs 2 (3%) anemia; 54 (74%) vs 17 (25%) had adverse events leading to dose reductions. Two patients died during the study (1 in each arm); neither death was considered related to study drug. CONCLUSIONS AND RELEVANCE: The primary endpoint, PFS, significantly favored alisertib plus paclitaxel over paclitaxel alone. Further investigation is warranted. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01091428.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Falchook G, Coleman RL, Roszak A, et al. Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol. 2019. PMID: 30347019. doi:10.1001/jamaoncol.2018.3773

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。